20231360 - Beitinjaneh Amer
-
Investigator:
Amer Beitinjaneh
Email
Coordinator:
IRB: 20231360
SDG: Cellular Therapy
Disease Site(s): Hodgkin Lymphoma,Non-Hodgkin Lymphoma
Sponsor: Indiana University
Enrolling Sites:
Coral Springs
Gables
Plantation
Sylvester
UMHTitle: A Phase I, Multicenter Study of CD4- directed chimeric antigen receptor engineered T-cells (CD4CAR) in patients with Relapsed or Refractory CD4+ Lymphoid Hematological Malignancies
Eligibility Criteria - NCT03829540 *This information has been extracted from " www.clinicaltrials.gov"
20220984 - Hernandez Aya Leonel
-
Investigator:
Leonel Hernandez Aya
Email
Coordinator:
IRB: 20220984
SDG: Cellular Therapy
Disease Site(s): Multiple
Sponsor: Immatics US Inc
Enrolling Sites:
Sylvester
Title: Phase 1/2 study evaluating genetically modified autologous T cells expressing a T-cell receptor recognizing a cancer/germline antigen as monotherapy or in combination with nivolumab in patients with recurrent and/or refractory solid tumors (ACTengine IMA203-101)
Eligibility Criteria - NCT03686124 *This information has been extracted from " www.clinicaltrials.gov"
20230190 - Jimenez Antonio
-
Investigator:
Antonio Jimenez
Email
Coordinator:
IRB: 20230190
SDG: Cellular Therapy
Disease Site(s): Leukemia, not otherwise specified
Sponsor: SCCC
Enrolling Sites:
Aventura
Coral Springs
Deerfield
Gables
Hollywood
Kendall
Plantation
Sylvester
UMHTitle: A Phase 1 Study of Venetoclax in Combination with Azacitidine (VEN/AZA) followed by Donor Lymphocyte Infusion (DLI) for Patients with Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)
Eligibility Criteria - NCT06158100 *This information has been extracted from " www.clinicaltrials.gov"
20231336 - Jimenez Antonio
-
Investigator:
Antonio Jimenez
Email
Coordinator:
IRB: 20231336
SDG: Cellular Therapy
Disease Site(s): Leukemia, not otherwise specified,Non-Hodgkin Lymphoma
Sponsor: NATIONAL MARROW DONOR PROGRAM
Enrolling Sites:
Coral Springs
Gables
Plantation
Sylvester
UMHTitle: A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients with Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Eligibility Criteria - NCT06001385 *This information has been extracted from " www.clinicaltrials.gov"
20210828 - Lekakis Lazaros
-
Investigator:
Lazaros Lekakis
Email
Coordinator:
IRB: 20210828
SDG: Cellular Therapy
Disease Site(s): Non-Hodgkin Lymphoma
Sponsor: SCCC
Enrolling Sites:
Deerfield
Gables
Kendall
Plantation
Sylvester
UMHTitle: ML43165 - Single Arm Phase 2 Trial of an FDA Approved anti-CD19 CAR-T Therapy followed by Mosunetuzumab and Polatuzumab Consolidation for the Treatment of Refractory/Relapsed Aggressive NHL
Eligibility Criteria - NCT05260957 *This information has been extracted from " www.clinicaltrials.gov"
20240912 - Lekakis Lazaros
-
Investigator:
Lazaros Lekakis
Email
Coordinator:
IRB: 20240912
SDG: Cellular Therapy
Disease Site(s): Brain and Nervous System
Sponsor: Juno
Enrolling Sites:
Aventura
Coral Springs
Deerfield
Gables
Hollywood
Kendall
Plantation
Sylvester
UMHTitle: A Phase 1, Multicenter, Open-Label Study Of CC-97540 (BMS-986353), CD19-Targeted Nex-T Chimeric Antigen Receptor (CAR) T Cells, in Participants with Severe, Refractory Autoimmune Diseases: Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy or Systemic Sclerosis
Eligibility Criteria - NCT05869955 *This information has been extracted from " www.clinicaltrials.gov"
20210661 - Pereira Denise
-
Investigator:
Denise Pereira
Email
Coordinator:
IRB: 20210661
SDG: Cellular Therapy
Disease Site(s): Multiple Myeloma,Other Hematopoietic
Sponsor: CELGENE
Enrolling Sites:
Sylvester
Title: EXPANDED ACCESS PROTOCOL (EAP) FOR SUBJECTS RECEIVING IDECABTAGENE VICLEUCEL THAT IS NONCONFORMING FOR COMMERCIAL RELEASE
Eligibility Criteria - NCT04771078 *This information has been extracted from " www.clinicaltrials.gov"
20240449 - Pereira Denise
-
Investigator:
Denise Pereira
Email
Coordinator:
IRB: 20240449
SDG: Cellular Therapy
Disease Site(s): Brain and Nervous System
Sponsor: Kyverna Therapeutics Inc
Enrolling Sites:
Aventura
Deerfield
Gables
Hollywood
Kendall
Plantation
Sylvester
UMHTitle: A Phase 2, Open-Label, Multicentre Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Refractory Generalized Myasthenia Gravis (KYSA-6)
Eligibility Criteria - NCT06193889 *This information has been extracted from " www.clinicaltrials.gov"
20230616 - Spiegel Jay
-
Investigator:
Jay Spiegel
Email
Coordinator:
IRB: 20230616
SDG: Cellular Therapy
Disease Site(s): Multiple Myeloma
Sponsor: Caribou Biosciences
Enrolling Sites:
Gables
Plantation
SylvesterTitle: A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial)
Eligibility Criteria - NCT05722418 *This information has been extracted from " www.clinicaltrials.gov"
CCTL019B20031 - Wang, Trent
-
Investigator:
Trent Wang
Email
Coordinator:
IRB: 20190006
SDG: Cellular Therapy
Disease Site(s): Lymphoid Leukemia,Non-Hodgkin Lymphoma
Sponsor: NOVARTIS
Enrolling Sites:
Sylvester
Title: CCTL019B2003I: Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or large B-cell lymphoma patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release
Eligibility Criteria - NCT03601442 *This information has been extracted from " www.clinicaltrials.gov"